CPA4 has been previously reported to promote epithelial-mesenchymal transition in pancreatic cancer [45], cardiomyocyte hypertrophy and the growth of non-small cell lung cancer through positive regulation of the AKT signalling pathway [40, 46–48], and it is closely related to the development of a variety of cancers. Here, CPA4 is linked to familial pancreatic carcinoma.